Shares of Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) have received a consensus recommendation of “Buy” from the nine brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $26.29.
A number of equities research analysts have recently weighed in on EIGR shares. Oppenheimer set a $34.00 target price on shares of Eiger Biopharmaceuticals and gave the company a “buy” rating in a research note on Thursday, December 7th. Zacks Investment Research lowered shares of Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Wedbush reaffirmed a “buy” rating on shares of Eiger Biopharmaceuticals in a research note on Wednesday, October 25th. Ladenburg Thalmann Financial Services started coverage on shares of Eiger Biopharmaceuticals in a research note on Wednesday, January 3rd. They set a “buy” rating and a $32.00 target price on the stock. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $17.00 target price (down previously from $35.00) on shares of Eiger Biopharmaceuticals in a research note on Tuesday, January 16th.
A number of large investors have recently bought and sold shares of EIGR. Susquehanna International Group LLP bought a new stake in Eiger Biopharmaceuticals during the second quarter worth about $114,000. Wedbush Securities Inc. bought a new stake in Eiger Biopharmaceuticals during the third quarter worth about $114,000. Bank of New York Mellon Corp boosted its stake in Eiger Biopharmaceuticals by 6.4% during the second quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 871 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Eiger Biopharmaceuticals by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock worth $126,000 after acquiring an additional 8,748 shares in the last quarter. Finally, OxFORD Asset Management LLP bought a new stake in Eiger Biopharmaceuticals during the third quarter worth about $147,000. 47.06% of the stock is currently owned by institutional investors and hedge funds.
Shares of Eiger Biopharmaceuticals (NASDAQ EIGR) traded down $0.30 on Tuesday, hitting $8.20. 99,565 shares of the stock were exchanged, compared to its average volume of 318,744. The company has a market cap of $86.23, a price-to-earnings ratio of -1.55 and a beta of 1.92. The company has a debt-to-equity ratio of 1.19, a current ratio of 5.78 and a quick ratio of 5.78. Eiger Biopharmaceuticals has a 52-week low of $6.10 and a 52-week high of $16.20.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.28) by $0.18. sell-side analysts expect that Eiger Biopharmaceuticals will post -4.56 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Eiger Biopharmaceuticals Inc (EIGR) Receives Average Rating of “Buy” from Brokerages” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/04/eiger-biopharmaceuticals-inc-eigr-receives-average-rating-of-buy-from-brokerages.html.
About Eiger Biopharmaceuticals
Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.